Literature DB >> 7769280

Topical immunoprophylaxis of respiratory syncytial virus (RSV)-challenged mice with RSV-specific immune globulin.

B S Graham1, Y W Tang, W C Gruber.   

Abstract

The modulatory effects of passive antibody on viral replication, illness, and immunity were investigated in a murine model of respiratory syncytial virus (RSV) infection. Nasally administered RSV-specific immune globulin (RSVIG) given prophylactically in a large volume (100 microL) reduced illness and RSV replication in lung after primary challenge. However, passive antibody treatment diminished the host antibody response to primary RSV infection. This resulted in greater susceptibility to reinfection and an alteration in the composition of the immune response after rechallenge. RSV infection of lung during primary infection was necessary for complete protection of lung from RSV rechallenge. Nasal infection alone during primary infection was not sufficient to protect against RSV rechallenge of lung, suggesting that the immune responses in the murine system are compartmentalized. The influence of compartmentalized immunity and modulation of immune responses will be important considerations as new approaches for topical immunoprophylaxis of RSV are developed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769280     DOI: 10.1093/infdis/171.6.1468

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

Review 1.  Intranasal antibody prophylaxis for protection against viral disease.

Authors:  R Weltzin; T P Monath
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

2.  Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice.

Authors:  C Bourgeois; J B Bour; L S Aho; P Pothier
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

3.  Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model.

Authors:  Jie Liu; Tracy J Ruckwardt; Man Chen; Teresa R Johnson; Barney S Graham
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

4.  A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo.

Authors:  John V Williams; Zhifeng Chen; Gabriella Cseke; David W Wright; Christopher J Keefer; Sharon J Tollefson; Ann Hessell; Amy Podsiad; Bryan E Shepherd; Pietro Paolo Sanna; Dennis R Burton; James E Crowe; R Anthony Williamson
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

5.  Blockade of the Adenylate Cyclase Toxin Synergizes with Opsonizing Antibodies to Protect Mice against Bordetella pertussis.

Authors:  Andrea M DiVenere; Dzifa Amengor; Rui P Silva; Jory A Goldsmith; Jason S McLellan; Jennifer A Maynard
Journal:  mBio       Date:  2022-08-03       Impact factor: 7.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.